A federal advisory panel voted Thursday to soften rules on seven peptides, including BPC-157 and TB-500. The vote was razor-thin. It is not binding. The FDA has given no clear statement on whether it will follow the advice. The move came after weeks of community hearings. Wellness backers pushed hard for wider access. RFK Jr. was among them. Critics say these compounds have no real proof of safety or help for most uses. The call could reshape how the agency handles a part of the wellness market that is expanding rapidly. Market observers are watching to see if the FDA follows through on the vote. A spokesperson for the agency offered no set date for a response. Backers argue the change would broaden access to products that users favor. Health groups warn that looser rules could leave gaps in oversight across a quickly growing market. The advisory vote only sets up a possible shift, and the final decision rests with the federal regulator.